| Company | Reason for receipt of fees | Total amount received |
|---|---|---|
| Oxford Centre for Triple Value Healthcare | We will work with pharmaceutical companies as part of a non branded programme of work to increase value. We will not endorse or promote any individual products | £50000- £100000 |
| Company | Reason for receipt of fees | Total amount received |
|---|---|---|
| NHS | we work with the NHS to help it increase value in healthcare | £100000+ |
Oxford Centre for Triple Value Healthcare is a social enterprise that gives 50% of any surplus to good causes (published annually). The remainder of our surplus goes to R&D and staff. We are a mission drive organisation with the goal to create more sustainable universal healthcare systems focussed on better outcomes for individuals and populations.
| Company | Reason for receipt of fees | Total amount received |
|---|---|---|
| PricewaterhouseCoopers LLP | I am a partner at PwC. As a partnership we serve a number of clients in the public sector (including the NHS), private sector and pharmaceutical and life science companies. | £100000+ |
All of the organisations to whom PwC provide services might be said to have a vested interest in avoiding a reduction in over diagnosis, most obviously private sector and pharmaceutical and life science (PLS) companies. However, the majority of the work I personally do is with the NHS, which has its own possible vested interests in continuing to over diagnose, as it could be seen as a means to demand more resources. PwC's work, however, is firmly fixed on finding ways for public, private and PLS companies to make a greater value contribution to health and well being, and therefore in the reduction of over diagnosis.